Clinical Observation Of A New Oral Anticoagulant Rivaroxaban In The Treatment Of Acute Pulmonary Thromboembolism

Objective:The cases of acute pulmonary thromboembolism in the First Affiliated Hospital of Xinjiang Medical University were analyzed before and after treatment of rivaroxaba and warfarin.After the clinical symptoms and anticoagulant treatment,the changes of pulmonary artery obstruction index and related indexes were applied to the patients,and the new type of anticoagulant and traditional anticoagulant drugs were compared.The difference of pulmonary artery obstruction index,clinical symptoms and risk of bleeding after treatment can guide clinical anticoagulation therapy.Methods: A total of 64 patients with acute pulmonary thromboembolism who received anticoagulation therapy at the First Affiliated Hospital of Xinjiang Medical University in recent 3 years were divided into 32 cases in warfarin group and 32 cases in rivaroxaban group.Analysis of two groups of patients after anticoagulation pulmonary artery obstruction index and improvement of clinical symptoms and bleeding risk.Using SPSS22.0 statistical software to process the data,p <0.05 for the difference was statistically significant.Results:(1)The pulmonary artery obstruction index was positively correlated with the severity of the disease,right ventricular diameter and cardiac troponin,but negatively correlated with oxygen partial pressure and carbon dioxide reaction.(2)The most common clinical symptom in all study patients was dyspnea(65.62%),followed by chest pain.(3)Compared with before treatment,the pulmonary arterial obstruction index,clinical symptoms,vital signs and laboratory indexes of the two groups of patients improved significantly after treatment(p<0.05);There was no significant difference between the above indicators,and the difference was not statistically significant(p>0.05).(4)There were 6 cases of slight hemorrhage in warfarin group and 2 cases of rivaroxaban group.The incidence of hemorrhage in rivaroxaban group was lower than warfarin,but the difference was not statistically significant.Conclusions:(1)Patients with acute pulmonary thromboembolism have the most common clinical manifestations of dyspnea.(2)Rivaroxaban and warfarin can significantly improve the pulmonary artery obstruction index,clinical symptoms,vital signs and laboratory indexes in patients with acute pulmonary thromboembolism.(3)The treatment of APTE by rivaroxaban has lower bleeding risk and is more convenient for long-term anticoagulation treatment of APTE patients.(4)The pulmonary artery obstruction index is closely related to the severity of the disease and contributes to severity assessment.